SYSA1902 Biosimilar Proves Equivalent to Reference Ustekinumab in Plaque Psoriasis

How Early Adopters Are Shaping the Future of Biosimilars

November 24th 2024

By Skylar Jeremias

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and cost savings.

Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy

November 23rd 2024

By Deana Ferreri, PhD

In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-positive advanced gastric cancer patients.

The Top 5 Biosimilar Articles for the Week of November 18

November 22nd 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of November 18, 2024.

Webinar: Streamlining the Regulatory Process to Advance Access to Biosimilars

November 21st 2024

By The Center for Biosimilars Staff

This webinar celebrating Global Biosimilars Week was hosted by The Center for Biosimilars® in partnership with the International Generics and Biosimilars Association.

Boosting Health Care Sustainability: The Role of Biosimilars in Latin America

November 21st 2024

By Skylar Jeremias

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.

Financial Incentives Boost Oncology Biosimilar Adoption, but Costs Remain Unchanged

November 20th 2024

By Skylar Jeremias

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, biosimilar use in oncology significantly increased.

Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data

November 19th 2024

By Skylar Jeremias

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.

BioRationality: A Proposal to Create a New Association With Rational Scientific Agenda

November 18th 2024

By Sarfaraz K. Niazi, PhD

Can Global Policies to Boost Biosimilar Adoption Work in the US?

November 17th 2024

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.

Subcutaneous Infliximab CT-P13 Superior to Placebo as Maintenance Therapy for IBD

November 16th 2024

By Deana Ferreri, PhD

In 2 randomized controlled trials of maintenance therapy for inflammatory bowel disease (IBD), the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to placebo in patients with Crohn disease and ulcerative colitis.